Benefit of Single-Agent Carboplatin in Vulnerable, Elderly Patients With Ovarian Cancer

The EWOC-1 trial looked at single-agent carboplatin in  vulnerable, elderly patients with stage III/IV epithelial ovarian cancer vs weekly or every 3 weeks carboplatin/paclitaxel.

Source: CancerNetwork - June 5, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news